GNLX
Genelux Corporation
$4.96
+$0.32(+6.90%)
38
Overall
40
Value
36
Tech
--
Quality
Market Cap
$172.37M
Volume
125.61K
52W Range
$1.99 - $8.54
Target Price
$19.00
Company Overview
| Mkt Cap | $172.37M | Price | $4.96 |
| Volume | 125.61K | Change | +6.90% |
| P/E Ratio | -5.8 | Open | $4.61 |
| Revenue | $8.0K | Prev Close | $4.64 |
| Net Income | $-29.9M | 52W Range | $1.99 - $8.54 |
| Div Yield | N/A | Target | $19.00 |
| Overall | 38 | Value | 40 |
| Quality | -- | Technical | 36 |
No chart data available
About Genelux Corporation
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Latest News
Genelux Corp.’s OnPrime Study: A Potential Game-Changer in Ovarian Cancer Treatment
TipRanks Clinical-Trials-Auto-Generated Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GNLX | $4.96 | +6.9% | 125.61K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |